Back to top
more

AcelRx Pharmaceuticals, Inc. (ACRX)

(Delayed Data from NSDQ)

$1.78 USD

1.78
710,556

0.00 (0.00%)

Updated Nov 12, 2019 04:00 PM ET

Add to portfolio

1-Strong Buy 1        

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.51%
17.57%
9.27%
4.95%
1.80%
10.51%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | F Growth | C Momentum | F VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Brokerage Reports

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

Research for ACRX

 

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

0 items in cart

AcelRx Pharmaceuticals, Inc. [ACRX]

Reports for Purchase

Showing records 1 - 20 ( 125 total )

Company: AcelRx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 1

10/08/2019

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for ACRX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: AcelRx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 2

08/06/2019

Company Report

Pages: 5

2Q19 Recap: Focus on Access; Setting the Foundation for Growth; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: AcelRx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 3

06/06/2019

Company Report

Pages: 6

Continuing to Execute on Key Objectives for 2019; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: AcelRx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 4

05/09/2019

Company Report

Pages: 4

1Q19 Recap; Early Days, but We See Early Signs of Interest in Adopting DSUVIA; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: AcelRx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 5

04/12/2019

Daily Note

Pages: 3

Pooled Analysis of Over 800 Patients Validates DSUVIA''s Safety in Elderly Patients; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: AcelRx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 6

03/11/2019

Company Report

Pages: 7

Very Early Days But Already Some Encouraging Signs on the DSUVIA Launch; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: AcelRx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 7

02/01/2019

Daily Note

Pages: 3

Burn Symposium to Showcase the Elegant Simplicity of Non-Invasive DSUVIA; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: AcelRx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 8

01/15/2019

Daily Note

Pages: 4

Opioid Potency and Other Revelations from a Pooled Safety Analysis of DSUVIA; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: AcelRx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 9

12/12/2018

Company Report

Pages: 12

Key Takeaways From Analyst Day Ahead of DSUVIA Launch; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: AcelRx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 10

11/06/2018

Company Report

Pages: 8

DSUVIA Approved; Launch Planned for 1Q19; Raise PT to $9

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: AcelRx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 11

10/15/2018

Company Report

Pages: 7

DSUVIA Poised for FDA Approval on Positive AdCom Vote; Raise PT to $8

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: AcelRx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 12

10/10/2018

Daily Note

Pages: 4

DSUVIA Briefing Docs Benign and Supportive of Approval; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 10.00

Research Provided by a Third Party

Company: AcelRx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 13

08/07/2018

Company Report

Pages: 8

2Q18 Recap: We Remain Confident Heading Into DSUVIA AdCom; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: AcelRx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 14

05/29/2018

Company Report

Pages: 9

We See Two Approvals and a Resubmission by Year End; Raise PT to $7

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: AcelRx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 15

03/09/2018

Company Report

Pages: 6

4Q Recap: Dsuvia NDA Resubmission in 2Q18; Launch Likely in 1Q19; Nudge PT to $6

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party

Company: AcelRx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 16

11/29/2017

Industry Report

Pages: 3

Coverage Update - Healthcare

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Company: AcelRx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 17

11/29/2017

Company Report

Pages: 4

We are placing shares of ACRX Under Review, and transferring coverage to ROTH Capital Research due to the departure of the covering analyst.

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: AcelRx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 18

11/10/2017

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: AcelRx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 19

11/10/2017

Company Report

Pages: 12

Mgt Clarifies FDA’s Thinking on Dsuvia CRL; Type A Mtg in Dec

Provider: Roth Capital Partners, Inc.

Analyst: HIGGINS M

Price: 25.00

Research Provided by a Third Party

Company: AcelRx Pharmaceuticals, Inc.

Industry: Medical - Drugs

Record: 20

10/27/2017

Company Report

Pages: 7

Despite CRL, We Still Believe Dsuvia''s Profile Is Ideally Positioned for Success; Reduce PT to $5

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 25.00

Research Provided by a Third Party